Related Experiment Videos
Tamoxifen-induced thrombocytopenia
J C Yao1, N Thomakos, P McLaughlin
1Division of Medicine, The University of Texas M.D. Anderson Cancer Center, Houston 77030, USA.
American Journal of Clinical Oncology
|October 16, 1999
Summary
Tamoxifen, a breast cancer drug, can rarely cause thrombocytopenia (low platelet count). This case shows tamoxifen-induced thrombocytopenia resolving upon drug withdrawal and recurring upon re-administration.
Area of Science:
- Oncology
- Hematology
- Pharmacology
Background:
- Tamoxifen is a widely used adjuvant therapy for breast cancer.
- Thrombocytopenia is a potential, though rare, adverse effect of tamoxifen treatment.
Observation:
- A case study detailing a patient who developed thrombocytopenia 6 months into adjuvant tamoxifen therapy for breast cancer.
- The patient had not received concurrent chemotherapy or radiation, isolating tamoxifen as the likely cause.
Findings:
- Thrombocytopenia resolved after discontinuing tamoxifen.
- The low platelet count recurred upon restarting tamoxifen and resolved again after its second withdrawal.
- Platelet counts normalized after switching to anastrozole, with sustained normal levels for over 6 months.
Implications:
- This case highlights the importance of monitoring platelet counts in patients receiving tamoxifen.
- It suggests a causal link between tamoxifen and thrombocytopenia, reinforcing the need for careful consideration of alternative therapies.
- The findings support the use of alternative endocrine therapies like anastrozole in cases of tamoxifen-induced adverse events.